Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2015 1
2017 1
2018 5
2021 1
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ. Javle M, et al. Among authors: king g. Oncologist. 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. Oncologist. 2023. PMID: 37390492 Free PMC article. Review.
Fibroblast growth factor receptors (FGFR) are emerging as an important therapeutic target for patients with advanced, refractory cancers. Most selective FGFR inhibitors under investigation show reversible binding, and their activity is limited by acquired drug resistance. …
Fibroblast growth factor receptors (FGFR) are emerging as an important therapeutic target for patients with advanced, refractory cancers …
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
Coveler AL, Pillarisetty VG, Koh WJ, Zhen DB, Park JO, King GG, Sham JG, Hannan LM, Mann GN, Baker KK, Redman MW, Swanson PE, Chiorean EG, Whiting SH. Coveler AL, et al. Among authors: king gg. Pancreas. 2023 May 1;52(5):e282-e287. doi: 10.1097/MPA.0000000000002253. Epub 2023 Oct 2. Pancreas. 2023. PMID: 37782886
OBJECTIVES: Pancreatic ductal adenocarcinoma (PDA) is the third most common cause of cancer death in the United States. Most patients who undergo resection develop recurrence. ...
OBJECTIVES: Pancreatic ductal adenocarcinoma (PDA) is the third most common cause of cancer death in the United States. Most patients …
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
King G, Javle M. King G, et al. Curr Oncol Rep. 2021 Jul 16;23(9):108. doi: 10.1007/s11912-021-01100-3. Curr Oncol Rep. 2021. PMID: 34269915 Review.
PURPOSE OF REVIEW: Cholangiocarcinoma is an aggressive cancer with a poor prognosis and limited treatment. Gene sequencing studies have identified genetic alterations in fibroblast growth factor receptor (FGFR) in a significant proportion of cholangiocarcinoma (CCA) patien …
PURPOSE OF REVIEW: Cholangiocarcinoma is an aggressive cancer with a poor prognosis and limited treatment. Gene sequencing studies ha …
Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
King GT, Sharma P, Davis SL, Jimeno A. King GT, et al. Drugs Today (Barc). 2018 Feb;54(2):103-122. doi: 10.1358/dot.2018.54.2.2776626. Drugs Today (Barc). 2018. PMID: 29637937 Review.
The recent development of monoclonal antibodies that disinhibit the immune system from recognizing and attacking tumor cells has revolutionized the treatment of cancer. Among these agents are drugs that specifically block cytotoxic T-lymphocyte protein 4 (CTLA-4), programm …
The recent development of monoclonal antibodies that disinhibit the immune system from recognizing and attacking tumor cells has revolutioni …
Use of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malignancies receiving oxaliplatin-based chemotherapy: Study protocol for a randomized, controlled pilot and feasibility study.
Cohen SA, Veleber S, Siman J, Guthrie KA, McMillen K, Heit M, Wadhera S, Daniels J, Hansen K, Jacoby M, Taromina K, Chin S, Romeo M, Langley BO, Coveler AL, Hannan LM, King G, Purcell T, Safyan RA, Shankaran V, Zhen DB, Chiorean EG, Greenlee H. Cohen SA, et al. Among authors: king g. Contemp Clin Trials. 2023 Aug;131:107273. doi: 10.1016/j.cct.2023.107273. Epub 2023 Jun 26. Contemp Clin Trials. 2023. PMID: 37380021
KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas.
Diehl AC, Hannan LM, Zhen DB, Coveler AL, King G, Cohen SA, Harris WP, Shankaran V, Wong KM, Green S, Ng N, Pillarisetty VG, Sham JG, Park JO, Reddi D, Konnick EQ, Pritchard CC, Baker K, Redman M, Chiorean EG. Diehl AC, et al. Among authors: king g. Oncologist. 2022 Dec 9;27(12):1025-1033. doi: 10.1093/oncolo/oyac179. Oncologist. 2022. PMID: 36124727 Free PMC article.
MATERIALS AND METHODS: We retrospectively identified patients with advanced PDA who received first-line therapy and underwent blood and/or tumor genomic sequencing at the University of Washington between 2013 and 2020. We examined the incidence of KRAS mutati …
MATERIALS AND METHODS: We retrospectively identified patients with advanced PDA who received first-line therapy and underwent blood and/or t …
Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World.
King G, Ittershagen S, He L, Shen Y, Li F, Villacorta R. King G, et al. Adv Ther. 2022 Dec;39(12):5433-5452. doi: 10.1007/s12325-022-02317-9. Epub 2022 Oct 5. Adv Ther. 2022. PMID: 36197644 Free PMC article.
INTRODUCTION: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a common cancer with poor survival outcomes. Although treatment options are limited, real-world treatment patterns and outcomes are not well understood, particularly beyond first-line treatment. ...
INTRODUCTION: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a common cancer with poor survival outcomes. Although treatment …
14 results